SEC Form 4 · accession 0000899243-19-002504
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick J Mahaffy
Officer — See Remarks · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 4, 2019 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $25.75 | Feb 1, 2019 | A | 200,000 | A | — | Feb 1, 2029 | Common Stock | 200,000 | 200,000 | D |
| Stock Option (right to buy)F2 | $25.75 | Feb 1, 2019 | A | 100,000 | A | — | Feb 1, 2029 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The option shall vest as to 25% of the shares on February 1, 2020, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
- F2The option shall vest in the event the Company's Product Revenues for the Company's fiscal year ending December 31, 2019 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board of Directors on December 6, 2018.
Remarks
President and Chief Executive Officer